Colorectal and Lung Tumoroids are Now Available NEW Blog Post - Progressing Ex Vivo Gene Editing Innovations with High-Quality Leukopaks Learn More about Discovery's AI-Annotated FFPE Tissues and DiscoverAI Tissue Analysis NEW Blog Post - Leverage Permeabilized Hepatocytes for Difficult Drug Compounds in Metabolism Studies Discovery Announces Upcoming Launch of Tumoroids at Precision Med Tri-Con

AI-Powered Pathology Solutions

Discovery’s partnership with industry leader PathAI leverages artificial intelligence (AI) to provide unparalleled accuracy and speed in digital pathology assessments anchored by enhanced data quality.

Discovery’s AI Journey

AI-Annotated FFPE Tissues with Precise Tumor Content Quantification

Discovery has deployed PathAI’s AISight^® workflow solutions in our pathology workflow, enabling a new level of precision in tumor content quantification. AI-annotation is able to calculate tumor percent at a decimal-point level of precision, surpassing the traditional qualitative assessments of pathologists and empowering faster turnaround times for large-scale research projects.

ArtifactDetect automatically identifies potential histology and scanning QC issues.
TumorDetect identifies and quantifies cancer area, cancer stroma, and necrosis.

AISight^® is for Research Use Only in the US; AISight^® Dx is CE-IVD marked in the EEA, UK, and Switzerland. ArtifactDetect and TumorDetect are research use only products available on AISight^® Image Management System, not for use in diagnostic procedures.

DiscoverAI: A Fit-for-Purpose AI Analysis

DiscoverAI, powered by PathAI, is the industry’s first joint offering that delivers quantitative characterization of the tumor microenvironment. It provides new insights through quantitative, human-interpretable features (HIFs) that define cell counts and densities by cell type and tumor region. As part of a comprehensive suite, DiscoverAI enables hypothesis-driven analysis, uncovering spatial insights and relationships that are beyond human pattern recognition.

PathAI offers a range of additional analysis solutions, including biomarker quantification and discovery, biomarker pre-screening and prediction, as well as non-oncology analyses for indications such as MASH, IBD, and Celiac.

Contact Us Today

Privacy Settings

AI-Powered Pathology Solutions

Discovery’s AI Journey

AI-Annotated FFPE Tissues with Precise Tumor Content Quantification

DiscoverAI: A Fit-for-Purpose AI Analysis

Contact Us Today

Gentest Services

MARKETS WE SERVE

COMPANY

Markets We Serve

Resources

Popular Keywords

Categories,Pages

Quick Links

Technologies

Development and Clinical Trial Solutions

Our Mission

Technologies

Development and ClinicalTrial Solutions

Post-Approval Services

Development and Clinical
Trial Solutions

Development and Clinical
Trial Solutions